Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications
Dermatology
Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.
Drs. Maurer, Ensina, Saini, and Kim provide expert insights to questions regarding emerging treatment, pathophysiology and neuronal sensitization in CSU.
New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management
Dermatology
Review the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies.
Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for Patient Management
Dermatology
A review of disease burden and treatment needs in PN and CSU, and how current and emerging therapies can impact patient management in these respective diseases.
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis
Dermatology
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.
ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management
Gastroenterology
Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
